Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): A randomised, placebo-controlled, phase 3 trial

The Lancet

Volumn 377, Issue 9774, 2011, Pages 1341-1352

  Gadde, Kishore M ^a   Allison, David B ^b   Ryan, Donna H ^c   Peterson, Craig A ^e   Troupin, Barbara ^e   Schwiers, Michael L ^d   Day, Wesley W ^e  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c PENNINGTON BIOMEDICAL RESEARCH CENTER   (United States)

^d Medpace ^*  (United States)

^e Menlo Park and VIVUS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; ANTIDEPRESSANT AGENT; ANTIHYPERTENSIVE AGENT; C REACTIVE PROTEIN; CHOLESTEROL; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; PHENTERMINE; PLACEBO; TOPIRAMATE; TRIACYLGLYCEROL;

ABDOMINAL OBESITY; ADULT; AGED; ANXIETY DISORDER; ARTICLE; BODY COMPOSITION; BODY MASS; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; COMORBIDITY; COMPARATIVE STUDY; CONSTIPATION; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; DEPRESSION; DIASTOLIC BLOOD PRESSURE; DIET; DIET RESTRICTION; DISEASE COURSE; DIZZINESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DUAL ENERGY X RAY ABSORPTIOMETRY; DYSGEUSIA; DYSLIPIDEMIA; FEMALE; GLUCOSE BLOOD LEVEL; HEART RATE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERTENSION; HYPERTRIGLYCERIDEMIA; IMPAIRED GLUCOSE TOLERANCE; INSOMNIA; INSULIN BLOOD LEVEL; INTERACTIVE VOICE RESPONSE SYSTEM; LIFE EXPECTANCY; LIFESTYLE MODIFICATION; LIPID BLOOD LEVEL; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OUTCOME ASSESSMENT; PARESTHESIA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; RISK REDUCTION; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE; WEIGHT REDUCTION; XEROSTOMIA;

EID: 79954561234     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(11)60205-5     Document Type: Article

References (35)

1. FB Hu, WC Willett, T Li Adiposity as compared with physical activity in predicting mortality among women N Engl J Med 351 2004 2694 2703 (Pubitemid 39665323)
2. SJ Olshansky, DJ Passaro, RC Hershow A potential decline in life expectancy in the United States in the 21st century N Engl J Med 352 2005 1138 1145 (Pubitemid 40365358)
3. T Pischon, H Boeing, K Hoffmann General and abdominal adiposity and risk of death in Europe N Engl J Med 359 2008 2105 2120
4. DB Allison, KR Fontaine, JE Manson Annual deaths attributable to obesity in the United States JAMA 282 1999 1530 1538 (Pubitemid 29504046)
5. DW Haslam, WPT James Obesity Lancet 366 2005 1197 1209 (Pubitemid 41393598)
6. R Stamler, J Stamler, WF Riedlinger Weight and blood pressure: findings in hypertension screening of 1 million Americans JAMA 240 1978 1607 1610 (Pubitemid 9047223)
7. P Hossain, B Kawar, M El Nahas Obesity and diabetes in the developing world-a growing challenge N Engl J Med 356 2007 213 215 (Pubitemid 46143224)
8. P Poirier, TD Giles, GA Bray Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss: an update of the 1997 American Heart Association scientific statement on obesity and heart disease from the Obesity Committee on the Council on Nutrition, Physical Activity, and Metabolism Circulation 113 2006 898 918
9. Look AHEAD Research Group Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: one-year results of the look AHEAD trial Diabetes Care 30 2007 1374 1383
10. TA Wadden, DS West, L Delahanty for the Look AHEAD Research Group The Look AHEAD study: a description of the lifestyle intervention and the evidence supporting it Obesity 14 2006 737 752 (Pubitemid 46219712)
11. Diabetes Prevention Program Research Group The Diabetes Prevention Program (DPP): description of lifestyle intervention Diabetes Care 25 2002 2165 2171
12. I Melnikova, D Wages Anti-obesity therapies Nat Rev Drug Discov 5 2006 369 370 (Pubitemid 43904927)
13. RB Rothman, MH Baumann, CM Dersch Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin Synapse 39 2001 32 41
14. GA Bray, P Hollander, S Klein A 6-month randomized, placebo-controlled, dose-ranging trial of topiramate for weight loss in obesity Obes Res 11 2003 722 733 (Pubitemid 41151598)
15. J Wilding, L van Gaal, A Rissanen A randomized double-blind placebo-controlled study of the long-term efficacy and safety of topiramate in the treatment of obese patients Int J Obes 28 2004 1399 1410 (Pubitemid 39481843)
16. J Rosenstock, P Hollander, KM Gadde A randomized, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of topiramate controlled release in the treatment of obese type 2 diabetic patients Diabetes Care 30 2007 1480 1486 (Pubitemid 46871158)
17. K Stenlöf, S Rössner, F Vercruysse Topiramate in the treatment of obese patients with drug-naïve type 2 diabetes Diabetes Obes Metab 9 2007 360 368 (Pubitemid 46502056)
18. H Toplak, A Hamann, R Moore Efficacy and safety of topiramate in combination with metformin in the treatment of obese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study Int J Obes 31 2007 138 146 (Pubitemid 46006027)
19. S Tonstad, A Tykarski, J Weissgarten Efficacy and safety of topiramate in the treatment of obese patients with essential hypertension Am J Cardiol 96 2005 243 251 (Pubitemid 40978583)
20. KM Gadde, DB Allison Combination therapy for obesity and metabolic disease Curr Opin Endocrinol Diabetes Obes 16 2009 353 358
21. K Kroenke, RL Spitzer, JBW Williams The PHQ-9: Validity of a brief depression severity measure J Gen Intern Med 16 2001 606 613 (Pubitemid 32823891)
22. KD Brownell The LEARN program for weight management 2000 The Life Style Company Dallas
23. K Posner, D Brent, C Lucas Columbia-Suicide Severity Rating Scale (C-SSRS) http://www.fda.gov/ohrms/dockets/ac/07/slides/2007-4306s1-01-CU-Posner- files/frame.htm (accessed Dec 20, 2010).
24. Food and Drug Administration Guidance for industry developing products for weight management. Draft guidance, revision 1 http://www.fda.gov/downloads/ Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071612.pdf February, 2007 (accessed Dec 20, 2010).
25. WC Knowler, E Barrett-Connor, SE Fowler Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin N Engl J Med 346 2002 393 403 (Pubitemid 34437694)
26. KM Gadde, GM Yonish, MS Foust A 24-week randomized controlled trial of VI-0521, a combination weight loss therapy, in obese adults Obes Res 14 2006 A17 (abstr 55-OR).
27. RL Kolotkin, RD Crosby Psychometric evaluation of the Impact Of Weight On Quality Of Life-Lite Questionnaire (IWQOL-Lite) in a community sample Qual Life Res 11 2002 157 171 (Pubitemid 34438162)
28. JE Ware Jr, CD Sherbourne The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection Med Care 30 1992 473 483
29. Food and Drug Administration FDA briefing document, NDA 22529, advisory committee for lorcaserin http://www.fda.gov/downloads/AdvisoryCommittees/ CommitteesMeetingMaterials/Drugs/ EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM225631.pdf Sept 16, 2010 (accessed Dec 30, 2010).
30. Food and Drug Administration FDA briefing document, NDA 200063, advisory committee for naltrexone/bupropion (Contrave) http://www.fda.gov/downloads/ AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM235671.pdf Dec 7, 2010 (accessed Dec 30, 2010).
31. J Toumilehto, J Lindstrom, JG Eriksson Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance N Engl J Med 344 2001 1343 1350 (Pubitemid 32378388)
32. D Rucker, R Padwal, SK Li Long-term pharmacotherapy for obesity and overweight: updated meta-analysis BMJ 335 2007 1194 1199 (Pubitemid 350273303)
33. SR Smith, NJ Weissman, CM Anderson Multicenter, placebo-controlled trial of lorcaserin for weight management N Engl J Med 363 2010 245 256
34. KM Gadde, GL Xiong Bupropion for weight reduction Exp Rev Neurother 7 2007 17 24 (Pubitemid 46105291)
35. FL Greenway, K Fujioka, RA Plodkowski Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial Lancet 376 2010 595 605